- Title
- Huntington's disease: A randomized, controlled trial using the NMDA-antagonist amantadine
- Creators
- L. Verhagen METMAN - Department of Neurological Sciences, Rush University/Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL, United StatesM. J MORRIS - Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, United StatesC FARMER - Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, United StatesM GILLESPIE - Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, United StatesK MOSBY - Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, United StatesJ WUU - Department of Neurological Sciences, Rush University/Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL, United StatesT. N CHASE - Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, United States
- Publication Details
- Neurology, Vol.59(5), pp.694-699
- Publisher
- Lippincott Williams & Wilkins
- Academic Unit
- Miller School of Medicine; UMMG Department of Neurology
- Language
- English
- Resource Type
- Journal article
- PMID
- 12221159
- Record Identifier
- 991031599768602976
Journal article
Huntington's disease: A randomized, controlled trial using the NMDA-antagonist amantadine
Neurology, Vol.59(5), pp.694-699
2002
PMID: 12221159
Metrics
13 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.52 Neurodegenerative Diseases
- 1.52.951 Huntington's Disease
- Web Of Science research areas
- Clinical Neurology
- ESI research areas
- Neuroscience & Behavior
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites